UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 511 - 525 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Actions of Two Main Metabolites of Propiverine (M-1 and M-2) on Voltage-Dependent L-Type Ca2+ Currents and Ca2+ Transients in Murine Urinary Bladder Myocytes - Abstract
Tuesday, 06 November 2007
Kyushu University.
read more

Primary Monosymptomatic Nocturnal Enuresis in Children and Adolescents - Abstract
Tuesday, 06 November 2007
Paediatric Urology Unit, Service de Chirurgie Viscerale Pediatrique, Hôpital Necker-Enfants Malades, Paris, France
read more

Nocturia: Etiology, Diagnosis, and Treatment - Abstract
Monday, 05 November 2007
Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
read more

Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome - Abstract
Monday, 05 November 2007
Department of Urology, New York University School of Medicine (VWN)
read more

Effect of Tolterodine on Sleep Structure Modulated by CYP2D6 Genotype - Abstract
Friday, 02 November 2007
Institute of Clinical Pharmacology, Charité – Universitätsmedizin Berlin, Berlin, Germany;
read more

Is Abuse Causally Related to Urologic Symptoms? Results from the Boston Area Community Health (BACH) Survey
Thursday, 01 November 2007
BERKELEY, CA (UroToday.com) — Over 25% of the United States adult population report either physical or sexual lifetime abuse. Medically, abuse is strongly associated with a range of gastroenterologic and genitourinary symptoms.
read more

Efficacy of Transcutaneous Electrical Nerve Stimulation in Children with Overactive Bladder Refractory To Pharmacotherapy - Abstract
Thursday, 01 November 2007
Division of Pediatric Urology, University of Iowa, Iowa City, Iowa.
read more

Therapeutic Effects of the Putative P2X(3)/P2X (2/3) Antagonist A-317491 on Cyclophosphamide-Induced Cystitis in Rats - Abstract
Wednesday, 31 October 2007
Department of Veterinary Pharmacology, Faculty of Agriculture, University of Miyazaki, Miyazaki, 889-2192, Japan,
read more

Correlation of Urinary Nerve Growth Factor Level with Pathogenesis of Overactive Bladder - Abstract
Wednesday, 31 October 2007
Department of Urology, Kawasaki Medical School, Kurashiki, Japan.
read more

Subcutaneous Tunneling of the Temporary Testing Electrode Significantly Improves the Success Rate of Subchronic Sacral Nerve Modulation (SNM) - Abstract
Tuesday, 30 October 2007
Department of Urology, University of Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany,
read more

Treating Patients with Overactive Bladder Syndrome with Antimuscarinics: Heart Rate Considerations - Abstract
Tuesday, 30 October 2007
Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA.
read more

Effects of IP-751, Ajulemic Acid, on Bladder Overactivity Induced by Bladder Irritation in Rats - Abstract
Monday, 29 October 2007
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
read more

Muscarinic Receptor Antagonists for Overactive Bladder - Abstract
Monday, 29 October 2007
Bristol Urological Institute, Southmead Hospital, Bristol, UK.
read more

Overactive Bladder in Children. Part 2: Management – Abstract
Friday, 26 October 2007
Section of Pediatric Urology, Department of Urology, New York Medical College, Valhalla, New York, USA.
read more

Once Daily Trospium Chloride Is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results from a Multicenter Phase III Trial – Abstract
Friday, 26 October 2007
Department of Urology, New York Presbyterian Hospital, Weill-Cornell Medical College, New York, New York 10021, USA.
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder